Stanley Bukofzer
2019 - DepoMed
In 2019, Stanley Bukofzer earned a total compensation of $1.7M as Senior Vice President and Chief Scientific and Technical Officer at DepoMed, a 23% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $247,833 |
|---|---|
| Salary | $500,016 |
| Stock Awards | $925,291 |
| Other | $14,120 |
| Total | $1,687,260 |
Bukofzer received $925.3K in stock awards, accounting for 55% of the total pay in 2019.
Bukofzer also received $247.8K in non-equity incentive plan, $500K in salary and $14.1K in other compensation.
Rankings
In 2019, Stanley Bukofzer's compensation ranked 6,744th out of 13,971 executives tracked by ExecPay. In other words, Bukofzer earned more than 51.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,744 out of 13,971 | 52nd |
Division Manufacturing | 2,570 out of 5,701 | 55th |
Major group Chemicals And Allied Products | 941 out of 2,200 | 57th |
Industry group Drugs | 796 out of 1,886 | 58th |
Industry Pharmaceutical Preparations | 581 out of 1,398 | 58th |
Source: SEC filing on April 20, 2020.
Bukofzer's colleagues
We found two more compensation records of executives who worked with Stanley Bukofzer at DepoMed in 2019.
News
Assertio Holdings CEO Arthur Higgins' 2020 pay falls 48% to $2.5M
April 12, 2021
Egalet CEO Arthur Higgins' 2019 pay rises 2% to $4.9M
April 20, 2020
DepoMed CEO Arthur Higgins' 2019 pay rises 2% to $4.9M
April 20, 2020
Egalet CEO Arthur Higgins' 2018 pay stays at $4.8M
November 6, 2019
DepoMed CEO Arthur Higgins' 2018 pay stays at $4.8M
April 8, 2019